
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc. has demonstrated significant growth in its EsoGuard product, with a marked increase in processed tests from 2,420 in Q1 to 3,147 in Q2, indicating strong market traction and potential for continued expansion. The company is well-positioned within the medical technology sector, with multiple products still in early commercialization stages but expected to grow substantially in the coming years, reflecting a promising pipeline for revenue generation. Furthermore, the entry of competitors into the market underscores the substantial opportunity available for PAVmed, enhancing the appeal of its offerings and signaling the potential for acquisition interest.
Bears say
PAVmed Inc. reported a pro forma net loss of $5.4 million, reflecting a deterioration from previous estimates and underscoring persistent financial challenges. The company's testing volume for its flagship product, EsoGuard, decreased in Q3, indicating potential issues with demand or market penetration. Additionally, the significant risks associated with liquidity, regulatory approvals, and commercialization factors further contribute to a negative outlook for the stock, exacerbated by reduced revenue estimates for 2024.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares